Executive Summary

1. Introduction

Antibody-drug conjugates, often called ADCs, have evolved into an important treatment approach, particularly in cancer care. They combine monoclonal antibodies with potent drug payloads to deliver targeted therapy to diseased cells while limiting effects on healthy tissue.

This report reviews global patent activity in ADC technologies, with a focus on recent trends in innovation and development. ADC patent protection spans multiple components, including the antibody, linker and conjugation chemistry, payload, formulation, and manufacturing methods. Understanding these layers is essential for evaluating ownership and overlap across technologies.

ADC Architecture - Component Overview

Patent filings have increased steadily in recent years, with a faster rise in granted patents. Activity is concentrated in major jurisdictions such as China, WIPO international filings, and the United States, with leading portfolios held by companies such as Regeneron, Seagen, Genentech, and Daiichi Sankyo.

2. Key Research Topics in ADC Patent Literature

The distribution of key research topics across ADC patent literature reveals clear clustering around core themes and emerging specialty areas. Antibody drugs, antibodies or antigens, target cells, disease treatment, and immune-related concepts appear most frequently, forming the foundation of ADC innovation.

Figure 1: Distribution of Key Research Topics in ADC Patent Literature - Classified by prevalence tier: Core · Platform · Moderate · Emerging · Niche

3. Key Components of ADC Technology

Antibody-drug conjugates are complex multi-component systems. Each element plays a distinct role in the mechanism of action and carries its own distinct patent landscape. Conjugation chemistry and formulation strategies are also critical dimensions that influence stability, pharmacokinetics, and IP strategy.

Table 1: Key Components of ADC Technology and Their Patent Focus Areas

4. Filing Trends: 2020 - 2025

Patent applications increased steadily from 1,891 in 2020 to a peak of 3,381 in 2024, before declining slightly to 2,789 in 2025.

Figure 2: Year-by-Year Growth of ADC Patent Applications (2020-2025)

5. Worldwide Distribution of Patent Activity

The geographic distribution of ADC patent activity reflects both the locations of the major innovators and the commercial markets they are seeking to protect. China leads in absolute publication volume, followed by WIPO international (PCT) filings and the United States.

Figure 3: Top 10 Jurisdictions by ADC Patent Publications (2020-2025) - Bar length reflects relative publication volume

6. Top Players in ADC Technologies

Patent portfolio leadership in the ADC space reflects significant investment by both established pharmaceutical companies and emerging biotechnology players. Regeneron leads, followed by Seagen, Genentech, and Daiichi Sankyo, reflecting deep expertise in antibody engineering and oncology.

Figure 4: Top 10 Current Assignees by ADC Patent Portfolio (2020-2025) - Bar length reflects relative patent count.

7. Technology Sub-Domain Analysis

ADC patent activity spans multiple technology sub-domains across the IPC/CPC classification system. Pharmaceuticals and biotechnology account for the largest share of patents, reflecting the core role of drug development and biological engineering.

Figure 5: ADC Patents by Technology Sub-Domain (2020-2025) - Bar length reflects proportional share of total patent activity

8. CPC Classification Analysis

The Cooperative Patent Classification (CPC) system provides granular insight into the specific technology areas driving ADC innovation. The most frequently occurring CPC codes confirm the primacy of oncology and highlight the depth of patent activity in antibody engineering and conjugation chemistry.

Figure 6: Top 10 CPC Codes in ADC Patent Filings by Patent Count (2020-2025)

Table 2: Definitions of Top 10 CPC Classification Codes in ADC Patent Filings

9. Highly Influential Patent Publications

Forward citation counts serve as an indicator of both scientific and strategic impact in patent analysis. The most highly cited ADC-related patent records reveal the foundations upon which the broader landscape is built. Dyne Therapeutics accounts for most of these highly cited patents, primarily focused on its anti-transferrin receptor antibody platform and muscle-targeting complexes for rare neuromuscular diseases.

MediLink Therapeutics also appears in the top cited records, highlighting the growing influence of Chinese players in ADC innovation. The presence of a CureVac coronavirus vaccine patent among the most cited records reflects increasing cross-technology interest between mRNA platforms and ADC delivery approaches.

Figure 7: Top Most-Cited ADC-Related Patent Records by Forward Citations (2020-2025) - Star rating is an illustrative citation impact indicator.

10. Conclusion

The ADC patent landscape is experiencing rapid growth and increasing competition. Patent applications rose from 1,891 in 2020 to 3,381 in 2024, with grants growing even faster, indicating a maturing intellectual property environment. China and the United States remain the leading jurisdictions, followed by PCT filings and Japan.

Leading portfolios are held by Regeneron, Seagen, Genentech, and Daiichi Sankyo. The presence of Chinese companies such as Jiangsu Hengrui and Sichuan Kelun Biotech highlights increasing global competition. Academic institutions continue to contribute to foundational innovations that underpin the broader landscape.

CPC classifications confirm a strong focus on oncology, with significant activity in antibody engineering, linker design, conjugation chemistry, and payload development. This reflects continued advancement beyond early-generation ADC technologies toward more sophisticated, differentiated platforms.